Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- PMID: 33378609
- PMCID: PMC7787219
- DOI: 10.1056/NEJMoa2035389
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Abstract
Background: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.
Methods: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2.
Results: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups.
Conclusions: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Copyright © 2020 Massachusetts Medical Society.
Conflict of interest statement
Dr. Baden reports being funded by the NIH to conduct clinical trials in collaboration with Crucell/Janssen and Moderna; Dr. Rouphael, receiving grant support from Pfizer, Merck, Sanofi–Pasteur, Eli Lilly, and Quidel; Dr. Creech, receiving grant support from Merck, consulting fees from Horizon Pharma and GSK, and fees for serving on a data and safety monitoring board from Astellas; Dr. Neuzil, receiving grant support from Pfizer; Dr. Graham, holding pending patent WO/2018/081318 on prefusion coronavirus spike proteins and their use and pending patent 62/972,886 on 2019-nCoV vaccine; Dr. Bennett, being employed by and owning stock and stock options in Moderna; Dr. Pajon, being employed by and owning stock in Moderna; Dr. Knightly, being employed by and owning stock and stock options in Moderna; Drs. Leav, Deng, and Zhou being employees of Moderna; Dr. Han, being employed by and owning stock and stock options in Moderna; Dr. Ivarsson, being employed by and owning share options in Moderna; Dr. Miller, being employed by and owning stock and stock options in Moderna; and Dr. Zaks, being employed by and owning stock options in Moderna. No other potential conflict of interest relevant to this article was reported.
Figures
Comment in
-
A New Vaccine to Battle Covid-19.N Engl J Med. 2021 Feb 4;384(5):470-471. doi: 10.1056/NEJMe2035557. Epub 2020 Dec 30. N Engl J Med. 2021. PMID: 33378607 Free PMC article. No abstract available.
-
COVID-19: Nobelpreiswürdiger Erfolg in der Impfstoff-Forschung.MMW Fortschr Med. 2021 Feb;163(2):24-25. doi: 10.1007/s15006-021-9577-4. MMW Fortschr Med. 2021. PMID: 33527275 Free PMC article. Review. German. No abstract available.
-
In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.Ann Intern Med. 2021 Mar;174(3):JC28. doi: 10.7326/ACPJ202103160-028. Epub 2021 Mar 2. Ann Intern Med. 2021. PMID: 33646836
-
Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.N Engl J Med. 2021 Apr 1;384(13):1273-1277. doi: 10.1056/NEJMc2102131. Epub 2021 Mar 3. N Engl J Med. 2021. PMID: 33657292 Free PMC article. No abstract available.
Similar articles
-
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22. N Engl J Med. 2021. PMID: 34551225 Free PMC article. Clinical Trial.
-
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1. Trials. 2021. PMID: 33849629 Free PMC article.
-
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial.Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. Lancet Respir Med. 2023. PMID: 37716365 Clinical Trial.
-
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis.BMC Infect Dis. 2024 Feb 21;24(1):234. doi: 10.1186/s12879-023-08754-3. BMC Infect Dis. 2024. PMID: 38383356 Free PMC article. Review.
-
Clinical Syndromes Related to SARS-CoV-2 Infection and Vaccination in Pediatric Age: A Narrative Review.Medicina (Kaunas). 2023 Nov 17;59(11):2027. doi: 10.3390/medicina59112027. Medicina (Kaunas). 2023. PMID: 38004076 Free PMC article. Review.
Cited by
-
Lipid nanoparticles-based RNA therapies for breast cancer treatment.Drug Deliv Transl Res. 2024 Jun 3. doi: 10.1007/s13346-024-01638-2. Online ahead of print. Drug Deliv Transl Res. 2024. PMID: 38831199
-
Persistence of COVID-19 Human Milk Antibodies After Maternal COVID-19 Vaccination: Systematic Review and Meta-Regression Analysis.Cureus. 2024 May 2;16(5):e59500. doi: 10.7759/cureus.59500. eCollection 2024 May. Cureus. 2024. PMID: 38826925 Free PMC article. Review.
-
Adjuvants for cancer mRNA vaccines in the era of nanotechnology: strategies, applications, and future directions.J Nanobiotechnology. 2024 Jun 2;22(1):308. doi: 10.1186/s12951-024-02590-6. J Nanobiotechnology. 2024. PMID: 38825711 Free PMC article. Review.
-
Supramolecular interaction in the action of drug delivery systems.Chem Sci. 2024 Apr 30;15(21):7811-7823. doi: 10.1039/d3sc04585d. eCollection 2024 May 29. Chem Sci. 2024. PMID: 38817563 Free PMC article. Review.
-
Vaccination induces broadly neutralizing antibody precursors to HIV gp41.Nat Immunol. 2024 Jun;25(6):1073-1082. doi: 10.1038/s41590-024-01833-w. Epub 2024 May 30. Nat Immunol. 2024. PMID: 38816615 Free PMC article.
References
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- UM1 AI148689/AI/NIAID NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- I01 BX003714/BX/BLRD VA/United States
- UL1 TR002541/TR/NCATS NIH HHS/United States
- UM1 AI069534/AI/NIAID NIH HHS/United States
- UM1 AI148685/AI/NIAID NIH HHS/United States
- P30 AI045008/AI/NIAID NIH HHS/United States
- UM1 AI068618/AI/NIAID NIH HHS/United States
- UM1 AI148684/AI/NIAID NIH HHS/United States
- L40 AI154610/AI/NIAID NIH HHS/United States
- UM1 AI068619/AI/NIAID NIH HHS/United States
- K23 AI159399/AI/NIAID NIH HHS/United States
- UM1 AI068636/AI/NIAID NIH HHS/United States
- UM1 AI069424/AI/NIAID NIH HHS/United States
- R01 AI134878/AI/NIAID NIH HHS/United States
- UM1 AI148576/AI/NIAID NIH HHS/United States
- UM1 AI068614/AI/NIAID NIH HHS/United States
- K12 HD052892/HD/NICHD NIH HHS/United States
- UM1 AI148373/AI/NIAID NIH HHS/United States
- Contract No. 75A50120C00034/US/United States/United States
- UM1 AI068635/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous